30 closest matches · ranked by relevance
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Overall Response Rate (Complete Response, Partial Response, or Hematologic Improvement) Defined by the International Working Group Criteria — 10 percentage of participants
Myelodysplastic Syndrome (MDS) · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Number of Participants Who Experienced Inducing or Boosting of a Cellular Immune Response — 5; 2 participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Donor Neutrophil Engraftment — 3; 7; 1 Participants
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Number of Participants With Response — 0; 0; 3; 1 participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome
Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants
Myeloid Malignancies · Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced Graft Failure — 0 Participants
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Number of Confirmed Responses (Complete Response, Partial Response, or Hematologic Improvement) Noted on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1; 0; 0…
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Polycythemia Vera · Essential Thrombocythemia · Primary Myelofibrosis
Primary: Influence of Pre- and Post- Incentives on Participation Rates. — 4; 6; 15; 69 Participants
Acute Myeloid Leukemia · Higher Risk Myelodysplastic Syndrome
Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg